The common recommendations for Cannabinoid Medications
                     The common 
recommendations for 
Cannabinoid Medications | 
Chronic Therapy
H T T P S : / / C H R O N I C T H E R A P Y . C O M . A U /
TGA Changes Allow for Streamlined Prescription 
Processes for Medical Cannabis
• The TGA has announced new changes to the medicinal cannabis prescription process.
• The changes al low GP’s to give out Special ised Access Schemes (SAS) and Authorised 
Prescriber applications by active ingredient or cannabinoid instead of the trade name.
• The TGA has announced fi ve diff erent cannabinoid categories that GP’s can prescribe to 
patients.
The TGA has announced five categories for medical 
cannabis products which are:
• Category 1 CBD Medical Cannabis Products: Products with more than 98% CBD.
• Category 2 CBD Dominant Medical Cannabis Products: Products with less than 98% CBD 
and more than 60%.
• Category 3 Balanced Medical Cannabis Products: Products with less than 60% CBD and 
more than 40%.
• Category 4 THC Dominant Medical Cannabis Product: Products with 60%-98% THC.
• Category 5 THC Medical Cannabis Product: Products with more than 98% THC.
The changes can also reduce possible disputes of 
interest
• Prescribing products based on the active ingredient instead of the brand name is also 
more ethical, as it gives patients the freedom to choose the brand of their cannabis 
products, as long as they fal l  under the same category.
• Prescribers of cannabis products are required to apply for authorisation from their state 
or territory jurisdiction.
• Another aspect of the TGA changes is the simplifi ed requirements for being an 
authorised prescriber.
“Established History of use”
• Prescribers no longer need Human Rights and Ethics Committee (HREC) and special ist 
medical college endorsements when applying to the TGA.
• When prescribing cannabis, the Associate Professor has advised GPs to exercise 
caution.
CONCLUSION
There is sti l l  a lot unknown about medical cannabis, so these changes wil l  make it easier 
to research the eff ects of medical cannabis and allow patients more freedom to select the 
right product for their needs and means.
INFORMATION SOURCE
H T T P S : / / C H R O N I C T H E R A P Y . C O M . A U /